A Phase III Randomized Placebo-Controlled Trial to Evaluate Efficacy and Safety of Romosozumab in Men With Osteoporosis

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Globally, one in five men aged >50 years is predicted to experience an osteoporotic fracture. Because of the treatment gap in osteoporosis and the paucity of bone-forming agents for men, new osteoporosis treatments are needed.

Related collections

Author and article information

Journal

Title: The Journal of Clinical Endocrinology & Metabolism

Publisher: The Endocrine Society

ISSN (Print): 0021-972X

ISSN (Electronic): 1945-7197

Publication date Created: September 2018

Publication date Created: September 01 2018

Publication date Created: June 20 2018

Publication date Other: September 2018

Publication date (Print): September 01 2018

Publication date (Electronic): June 20 2018

Volume: 103

Issue: 9

Pages: 3183-3193

Affiliations

[1 ]New Mexico Clinical Research & Osteoporosis Center, Albuquerque, New Mexico

[2 ]Medical University of Lublin, Lublin, Poland

[3 ]Ghent University Hospital, Ghent, Belgium

[4 ]Bern University Hospital, University of Bern, Bern, Switzerland

[5 ]UCB Pharma, Brussels, Belgium

[6 ]Colorado Center for Bone Research, Lakewood, Colorado

[7 ]Miyauchi Medical Center, Osaka, Japan

[8 ]Amgen Inc., Thousand Oaks, California

[9 ]Amgen France, Paris, France

Article

DOI: 10.1210/jc.2017-02163

PubMed ID: 29931216

SO-VID: c2564f76-df9a-4732-8b58-1cc3f7c98a58

History

Data availability:

Comments

Comment on this article

scite_

Cited by 75

See all cited by